Gentamicin, while not as effective as ceftriaxone in clearing gonorrhoea infection, may be a suitable alternative treatment for patients who are intolerant or resistant to ceftriaxone, according to the G-ToG study.
Rapid identification of pathogens using a molecular point-of-care testing (POCT) significantly reduces intravenous antibiotic use and the duration of hospitalization among patients with acute lower respiratory tract infection (LRTI), a study presented at ATS 2019 shows.
Among patients chronically infected with hepatitis C virus (HCV), presenting with elevated blood pressure during initiation of antiviral therapy is associated with treatment failure, according to a study presented at the Asian Pacific Society of Cardiology (APSC) Congress 2019.
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
The low uptake of the human papillomavirus (HPV) vaccine in the US and strategies to improve HPV vaccine coverage were highlighted in two studies presented at the Pediatric Academic Societies annual meeting (PAS 2019).
The addition of the first-in-class direct lytic agent exebacase (lysin CF-301) to standard-of-care (SOC) antibiotics demonstrated efficacy against Staphylococcus aureus bacteraemia (SAB), particularly difficult-to-treat methicillin-resistant SA (MRSA), compared with SOC antibiotics alone, according to the results of a phase II trial presented at ECCMID 2019.
The novel human monoclonal antibody suvratoxumab yielded a trend toward reducing the incidence of Staphylococcus aureus pneumonia (SAP) in high-risk, mechanically-ventilated intensive care unit (MV ICU) patients with an acceptable safety profile, according to data from the phase II SAATELLITE* trial presented at ECCMID 2019.
The selective cap-dependent endonuclease inhibitor baloxavir marboxil (hereafter baloxavir) effectively improves influenza symptoms in adolescent patients and those at high risk for influenza complications, according to two subanalyses of the CAPSTONE studies presented at ECCMID 2019.
The novel pleuromutilin antibiotic lefamulin - now in an oral therapy form - has demonstrated a favourable safety and tolerability profile for community-acquired bacterial pneumonia (CABP) in the LEAP* 2 study, the same result seen for intravenous (IV) lefemulin in the original LEAP 1 study.